Literature DB >> 16531558

Rituximab in Churg-Strauss syndrome.

M Koukoulaki, K G C Smith, D R W Jayne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16531558      PMCID： PMC1798092          DOI： 10.1136/ard.2005.042937

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.

Authors:  M G Danieli; M Cappelli; G Malcangi; F Logullo; A Salvi; G Danieli
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

Review 2.  Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis.

Authors:  L Guillevin; R Cevallos; B Durand-Gasselin; F Lhote; B Jarrousse; P Callard
Journal:  Ann Med Interne (Paris)       Date:  1997

3.  Serum interleukin-5 levels in a case with allergic granulomatous angiitis.

Authors:  Y Shiota; H Matsumoto; Y Kanehisa; M Tanaka; K Kanazawa; J Hiyama; T Ono; M Marukawa; H Mashiba
Journal:  Intern Med       Date:  1997-10       Impact factor: 1.271

4.  T cell activation in rheumatoid synovium is B cell dependent.

Authors:  S Takemura; P A Klimiuk; A Braun; J J Goronzy; C M Weyand
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome.

Authors:  M Kiene; E Csernok; A Müller; C Metzler; A Trabandt; W L Gross
Journal:  Arthritis Rheum       Date:  2001-02

6.  Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.

Authors:  E Tatsis; A Schnabel; W L Gross
Journal:  Ann Intern Med       Date:  1998-09-01       Impact factor: 25.391

7.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

Authors:  A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

8.  Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides.

Authors:  M Gayraud; L Guillevin; P Cohen; F Lhote; P Cacoub; P Deblois; B Godeau; M Ruel; E Vidal; M Piontud; J P Ducroix; S Lassoued; B Christoforov; P Babinet
Journal:  Br J Rheumatol       Date:  1997-12

9.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

10.  Investigation of the role of B-cells in type 1 diabetes in the NOD mouse.

Authors:  F Susan Wong; Li Wen; Michelle Tang; Murugappan Ramanathan; Irene Visintin; Joanne Daugherty; Lynn G Hannum; Charles A Janeway; Mark J Shlomchik
Journal:  Diabetes       Date:  2004-10       Impact factor: 9.461
  10 in total
  20 in total

Review 1.  Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.

Authors:  Jeremy M Clain; Rodrigo Cartin-Ceba; Fernando C Fervenza; Ulrich Specks
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 3.  Targeted biologic approaches to the treatment of systemic vasculitis.

Authors:  Andreea Coca; Jennifer H Anolik
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

4.  Churg-Strauss syndrome successfully treated with rituximab.

Authors:  Kristin Kveim Dønvik; Roald Omdal
Journal:  Rheumatol Int       Date:  2009-09-30       Impact factor: 2.631

5.  Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis.

Authors:  Catherine E Najem; Rajwardhan Yadav; Elise Carlson
Journal:  BMJ Case Rep       Date:  2015-05-15

6.  [Pulmonary allergic reactions].

Authors:  A R Koczulla; B Beutel; T Greulich; A Jerrentrup; C Vogelmeier
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 7.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

Review 8.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Targeting the B cell in vasculitis.

Authors:  Michael Walsh; David Jayne
Journal:  Pediatr Nephrol       Date:  2008-10-18       Impact factor: 3.714

Review 10.  Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Authors:  Francesco Muratore; Giulia Pazzola; Alessandra Soriano; Nicolò Pipitone; Stefania Croci; Martina Bonacini; Luigi Boiardi; Carlo Salvarani
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.